SCHEMBL12340705

SCHEMBL12340705

CC(C)(C)OC(=O)N1CCC(C)(N2CCN(C3CCc4ccccc43)CC2)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 2/20 0.43
GPR119 Q8TDV5 2/20 0.42
KDM1A O60341 2/20 0.42
CHRNA7 P36544 1/20 0.41
DDB1 Q16531 1/20 0.41
CRBN Q96SW2 1/20 0.41
OPRM1 P35372 1/20 0.40
OPRD1 P41143 1/20 0.40
OPRK1 P41145 1/20 0.40
OPRL1 P41146 1/20 0.40
MTNR1B P49286 1/20 0.40
PRMT5 O14744 1/20 0.39
WDR77 Q9BQA1 1/20 0.39
MAPK1 P28482 1/20 0.39
KDM4E B2RXH2 1/20 0.39
PKM P14618 1/20 0.39
GPR84 Q9NQS5 1/20 0.39
TERT O14746 1/20 0.39
FNTA P49354 1/20 0.39
FNTB P49356 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6421245 0.89 NAMPT (0.49) NAMPTGPR119CHRNA7MTNR1BMAPK1
SCHEMBL12340701 0.87 NAMPT (0.40) NAMPTGPR119KDM1ACHRNA7DDB1
SCHEMBL6423382 0.83 CHRNA7 (0.51) NAMPTGPR119KDM1ACHRNA7OPRM1
SCHEMBL6421368 0.82 CHRNA7 (0.50) NAMPTGPR119KDM1ACHRNA7OPRM1
SCHEMBL12344401 0.76 CCR5 (0.68) GPR119KDM1AFNTAFNTB
SCHEMBL12340718 0.76 CCR5 (0.68) GPR119KDM1AFNTAFNTB
SCHEMBL12340725 0.74 CCR5 (0.61)
SCHEMBL30508342 0.74 FNTA (0.49) GPR119MTNR1BFNTAFNTB
SCHEMBL2571557 0.74 FNTA (0.49) GPR119MTNR1BFNTAFNTB
SCHEMBL13158177 0.74 FNTA (0.58) MTNR1BFNTAFNTB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9067921-B2 Piperazinylpiperidine derivatives as chemokine receptor antagonists INCYTE CORPORATION (US) 2015-06-30 US disclosed
US-20140155404-A1 PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS INCYTE CORPORATION (US) 2014-06-05 US disclosed
US-8680104-B2 Piperazinylpiperidine derivatives as chemokine receptor antagonists INCYTE CORPORATION (US) 2014-03-25 US disclosed
US-20120295912-A1 PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS INCYTE CORPORATION (US) 2012-11-22 US disclosed
US-8268826-B2 5-({4-[(3S)-4-(5-bromo-2,3-dihydro-1H-inden-1-yl)-3-methylpiperazin-1-yl]-4-methylpiperidin-1-yl}carbonyl)-4,6-dimethylpyrimidine; inflammatory diseases, immune diseases and viral infections; HIV INCYTE CORPORATION (US) 2012-09-18 US disclosed
US-7678798-B2 Piperazinylpiperidine derivatives as chemokine receptor antagonists INCYTE CORPORATION (US) 2010-03-16 US disclosed
US-20090197887-A1 PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS INCYTE CORPORATION 2009-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140155404-A1 PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS CCR5, CCR2, CXCR5 NAMPT 1537/4885GPR119 230/4885KDM1A 4097/4885
US-20120295912-A1 PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS CCR5, CCR2, CXCR5 NAMPT 1537/4885GPR119 230/4885KDM1A 4097/4885
US-20090197887-A1 PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS CCR5, CCR2, CXCR5 NAMPT 1537/4885GPR119 230/4885KDM1A 4097/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.